Assessment of efficy and safety of everolimus in Japanese patients with mRCC
Not Applicable
- Conditions
- renal cell carcinoma
- Registration Number
- JPRN-UMIN000009620
- Lead Sponsor
- Tokyo Afinitor Clinical Trial Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Unsuitable for everolimus treatment
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method